anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: The aim of this study was to translate and validate the "Music-Related Quality of Life Questionnaire" into Spanish (sMuRQoL) and assess its convergent validity and discriminative capacity by comparing its scores with the outcomes of the musical perception test Meludia.
METHODS: The sMuRQoL was completed by 129 patients: 55 cochlear implant (CI) users and 74 normal hearing (NH) individuals. Conducted in this study were an exploratory factor analysis, an evaluation of internal consistency, an assessment of score stability through test-retest reliability, a comparison of sMuRQoL scores between CI users and NH individuals and an examination of potential evidence of convergent validity and discriminative capacity of sMuRQoL in relation to other tools. This involved the comparison of the questionnaire scores with the Meludia outcomes.
RESULTS: The sMuRQoL demonstrated a two-dimensional structure. All the dimensions displayed high internal consistency (α = 0.879-0.945) and score stability (ICC = 0.890-0.942). There were significant differences in the Frequency test between NH and CI users (d = 1.19-1.45). There's evidence of convergent validity between the scores of the Frequency test and the results of Meludia (r = 0.242-0.645). Additionally, the Frequency test demonstrate a good discriminative capacity to identify patients with poorer musical perception.
CONCLUSIONS: The sMuRQoL is a reliable questionnaire, with adequate evidence of validity based on internal structure. This study provides an accessible, cost-effective, and quick-to-administer instrument in Spanish, optimizing available healthcare resources and bringing us closer to the patient needs.
The present invention relates to a stable and effective composition comprising uridine monophosphate, Vitamin В1 (thiamine), Vitamin В3 (nicotinamide), Vitamin В6 (pyridoxine), Vitamin В12 (cyanocobalamin) and folic acid in combination thereof, which aids the regeneration of the peripheral nerves and simultaneously provides uridine monophosphate, folic acid and vitamins, which deficiency in the human body leads to unwanted symptoms and the likelihood of pathological manifestations. According to the preferred embodiments of the invention, the amount of uridine monophosphate is 50 mg. The amount of Vitamin В1 is preferably 4 mg. The amount of Vitamin В3 is preferably 10 mg. The amount of Vitamin B6 is preferably 6 mg. The amount of Vitamin В12 is preferably 10 µg. The amount of folic acid is preferably 400 µg. The composition, according to the invention, contains as active ingredients the combination of uridine monophosphate, folic acid and Vitamins В1, В3, В6, В12, and it has been been found to aid the regeneration of peripheral nerves, achieving , increased nucleic acid and protein synthesis in neurons and stimulation of myelin sheath formation.
Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
This invention relates to a method of generating a personalized exercise program for a user. Fitness related data indicating an initial physical fitness shape of the user are acquired from the user and used for constructing a fitness proposal for the user. The constructing includes comparing the acquired fitness related data with reference fitness data for corresponding fitness categories, where the reference fitness data are selected in accordance to the acquired fitness related data and indicate a reference fitness shape for the user. A deviation indicator is determined for each of the categories indicating the deviation between the acquired fitness related data and the reference data within the same fitness category. The deviation indicators are subsequently presented to the user so as to indicate the initial physical fitness shape of the user compared to the reference fitness shape for each of the categories. First input data are then received from the user indicating the user's target level for each of the categories, and finally an exercise plan is composed based on the received user input, the composing being performed in accordance to a set of rules.
<P>PROBLEM TO BE SOLVED: To provide a remote entry system capable of directly receiving and acquiring evaluation data of an inspection result entered from a medical institution by a server computer.  <P>SOLUTION: In a clinical test, the remote entry system sends evaluation of the inspection result entered from a terminal computer 31 of the medical institution 3 to the server computer 11 of a case report support institution 1 for clinical tests. The server computer 11 creates a browser image plane 66 of inspection result data and an evaluation entry image plane 65 of a subject from the inspection result data sent from the terminal computer 31 in the past and sends it to the terminal computer 31 at evaluation of the subject. The terminal computer 31 displays the browser image plane 66 and the evaluation entry image plane 65 of the subject. Evaluation data of the subject entered into the evaluation entry image plane 66 is sent to the server computer 11.  <P>COPYRIGHT: (C)2004,JPO
INTRODUCTION: Awake surgery is now a common approach for the resection of glioma. One of the surgical complications is mini-stroke which take the form of periresectional small areas of brain ischemic lesions. The main objective of this study is to evaluate the association between factors related to anesthetic management and the risk of mini-stroke, in awake surgery for glioma resection.
METHODS: In this single-center retrospective study, all patients who were operated on, between 2011 and 2022, in awake conditions for a glioma resection, were retrospectively included. The studied anesthetic parameters included hemodynamic variables, fluid intake and urinary output. The primary endpoint was the presence of mini-stroke on a magnetic resonance imaging performed within the first 48 h postoperatively.
RESULTS: A total of 176 surgeries were included. Mini-stroke was present in 120/171 surgeries (70%), with a median volume of 1.2 interquartile range [0.4-2.2] cubic centimeters (cc). In a multivariable analysis, only the per operative urinary output was significantly associated with the incidence of postoperative mini-strokes (adjusted odd-ratio 0.65, 95% confidence interval 0.45-0.94, p = 0.02). No variables related to the anesthetic management were associated with the volume of postoperative mini-strokes. In particular, the time spent below 90% of the baseline systolic blood pressure was not associated with either the risk or the volume of mini-strokes.
CONCLUSION: During awake surgery for glioma resection, among several anesthesia related factors, only the per operative urinary output was associated with the incidence of postoperative mini-stroke.
Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
Constipation

In clinical trials, 224 of 1131 (20%) of patients treated with SUSTOL 10 mg reported constipation compared to 13% to 15% in the 5-HT3 receptor antagonist control arms. Hospitalization due to constipation or fecal impaction was reported in 5 SUSTOL-treated patients (0.3%). Monitor patients for the development of constipation while receiving treatment with SUSTOL taking into consideration the extended-release properties of the SUSTOL polymer formulation over at least 5 to 7 days, particularly in patients receiving opioid medications. Consider optimizing bowel regimens in patients using SUSTOL.

Progressive Ileus and Gastric Distention

SUSTOL may mask a progressive ileus and/or gastric distention. This should be particularly considered before use of SUSTOL in patients who have had recent abdominal surgery. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.
OBJECTIVE: To summarize the surgical accidents and postoperative complications of the treatment of recurrent shoulder dislocation by suture button fixation and bone occlusion, and to provide clinical reference.
METHODS: The clinical data of 16 patients with recurrent shoulder dislocation treated with modified arthroscopic Latarjet suture button fixation and bone occlusion between July 2017 and April 2023 were retrospectively analyzed. Among them, 15 were male and 1 was female. The age ranged from 16 to 45 years, with an average of 26 years. Admission examination showed the range of motion of shoulder joint was normal; the shoulder joint fear test was positive; En-face CT scan measured 10%-20% of the glenoid defects, averaging 13.4%; and MRI examination revealed bone Bankart injury. The disease duration ranged from 2 to 20 years, with an average of 7.1 years. The shoulder joint was dislocated 8- 45 times, with an average of 17.4 times, and the shoulder joint was unstable. The occurrence of surgical accidents and postoperative complications as well as corresponding measures and outcomes were recorded.
RESULTS: All the incisions healed by first intention without any complications such as incision infection or vascular injury. All 16 cases were followed up for an average of 3.6 years (range, 1-7 years), and no shoulder redislocation occurred. Four types of intraoperative surgical accidents and two types of postoperative complications occurred in the early stage of implementation of the technique. Intraoperative surgical accidents included 1 case of difficulty in passing subscapular muscle through coracotomy with large size, which was treated with exchange rod or finger through subscapular muscle split; 2 cases of coracoidal process fracture, of which 1 case was treated conservatively, and the other case was sutured to the base of tendon and fixed through tunnel; 1 case of glenoid fracture occurred in the glenoid tunnel, which was fixed with knot-free anchors; the posterior loop plate fixation was abnormal in 2 cases, of which 1 case was re-fixed and the other case was renovated. Postoperative complications included coracoid bone mass displacement in 1 case, conservative biceps rehabilitation was given to avoid premature external rotation; 1 case of radial nerve injury of healthy upper limb and musculocutaneous nerve injury of affected side was given oral medication and physiotherapy. The above conditions recovered well after corresponding treatment.
CONCLUSION: Suture button fixation with bone occlusion is a safe method for the treatment of recurrent shoulder dislocation. Careful operation should be performed during coracoid interception and glenoid tunnel drilling, especially in the fixation process.
The invention provides modified polyethyleneimine, and a preparing method and applications of the modified polyethyleneimine. The modified polyethyleneimine is prepared through modifying polyethyleneimine with different molecular weights with phenylboronic acid compounds. The modified polyethyleneimine has an active targeting property for tumor cell membranes, and can carry genes to form a gene vector composition used for gene therapy. The gene vector composition is uniform in particle size, proper in charge, stable in properties, low in cell toxicity, high in cell transfection efficiency, high in target power, and good in biocompatibility and biodegradability. The modified polyethyleneimine and the gene vector composition can be used for the gene therapy. Preparing processes of the modified polyethyleneimine and the gene vector composition are simple, high in reaction degree controllability and capable of industrial production.
Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
Social media have become crucial communication channels for human papilloma virus (HPV) patients to seek and receive social support that can benefit their physical and psychological health. To promote supportive communication on online social platforms, we analyzed 96,543 messages, including 7,407 posts and 89,136 comments, concerning social support on Baidu HPV Forum, one of China's largest online HPV support groups. We examined factors (i.e., threat and efficacy) in posts requesting social support associated with the amount of social support received in comments. Results revealed that the majority of social support messages received in comments represented informational support, whereas relatively few comments featured instrumental social support. Beyond that, high-threat, non-efficacy posts requesting social support received a greater amount of informational and emotional support in the comments than other types of posts requesting social support. Theoretical and practical implications of our study are discussed as well.
Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
Any number of factors could affect the dosage needs for an anti-epileptic medication, however, various lines of evidence suggest that characteristics of the patient's epilepsy itself could be important determinants. Baseline (i.e., at the start of the study) patient characteristics, particularly seizure frequency, may predict dosage needs when TOPAMAX® (topiramate) is initiated as monotherapy and titrated to an individualized optimal dose. Topiramate is an anti-epileptic drug that is approved for epilepsy either alone (i.e., monotherapy), or in combination with other anti-epileptic medications, in adults and children 2 years of age and above. This is a multicenter, outpatient, open-label, single-arm study to evaluate the dosing, tolerability, effectiveness and safety of topiramate as initial therapy for epilepsy in clinical practice. Patients who have been identified by their physicians as candidates for initial anti-epileptic monotherapy will be enrolled. Patients will begin therapy with topiramate tablets starting at 50 milligrams per day and be titrated to an individualized optimal dose, up to a maximum of 400 milligrams per day, by the end of week 6. Changes to this schedule will be based on a risk-benefit assessment of the patient's clinical condition by the investigator, such as tolerability, or reaching a stable dose sufficient to control their seizures. Treatment with topiramate will last for a total of 24 weeks. The primary outcome of the study is a comparison of the mean stabilized topiramate dose during the last 28 days of treatment for patients reporting 1 to 3 seizures during the 3 months prior to study entry versus patients reporting more than 3 seizures during the 3 months prior to study entry. The study hypothesis is that the average stabilized dose of topiramate will be lower in patients that have had fewer seizures in the 3 months prior to beginning the study. Topiramate tablets starting at 50 milligrams per day and titrated to an individualized optimal dose, up to a maximum of 400 milligrams per day by the end of week 6. Patients will take topiramate tablets by mouth twice a day (morning and evening) for 24 weeks.
The invention relates to a traditional Chinese medicine for treating spleen deficiency and blood stasis induced chronic hepatitis. Chronic hepatitis is a common disease, and has abdominal distension, poor appetite, nausea, vomiting and other symptoms, and affects the normal work and life of people. Many medicines for treating the chronic hepatitis exist in the current market, cannot radically treat the chronic hepatitis, and have poor curative effects. The traditional Chinese medicine for spleen deficiency and blood stasis induced chronic hepatitis is prepared to solve the above problem. The traditional Chinese medicine has the efficacy of invigorating the spleen and disinhibiting dampness, and activating blood circulation and dissipating blood stasis. The traditional Chinese medicine for treating spleen deficiency and blood stasis induced chronic hepatitis is prepared from pure traditional Chinese medicines, and comprises Salvia miltiorrhiza, stir-fried Atractylodes lancea, Herba Lycopi, wrinkled gianthyssop, Fructus Citri Sarcodactylis, orange peel, white peony root, Rhizoma Cyperi, Capillary Wormwood Herb, hawthorn fruits and Chinese angelica root.
The subjects were divided into the experimental group and the placebo group according to 3:1. The experimental group was inoculated with a dose of 50μg mRNA vaccine, and the placebo group was inoculated with a dose of placebo.
Biliary tract cancer is a group of highly heterogeneous and aggressive epithelial cancers, accounting for about 3% of all digestive system tumors. It is highly aggressive, and most of them are found in advanced stages, with extremely poor prognosis and a 5-year survival rate of less than 5%. The overexpression rate of HER2 in biliary tract tumors is about 26.5%, and the amplification rate is about 30.1%. In addition, HER2 mutations in biliary tract malignant tumors also include HER2 mutations. In addition, HER2 mutations in biliary malignant tumors also include HER2 mutations. Currently, anti-HER2 strategies have become a new hotspot for exploration in BTC. It is a single arm, open-label, phase II cinical trial conducted in China and plans to recruit 28 patients with HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma who have progressed through first-line treatment. The purpose of this study is to evaluate the efficacy and safety of second-line treatment with Disitamab Vedotin Plus Cadonilimab
This group will be maintaining their pre-study activity levels for the first 6 weeks of the study. Weekly surveys will be administered to monitor wellbeing and health throughout the intervention. Then the participants will be given access to all the Down Dog apps (both yoga and HIIT included) to use as the participants please for the following 6 weeks. A final wellbeing and health survey at the end of the second 6 weeks will be administered.
Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
The invention relates to a preparation method and a production method of a Chuanxiong decoction integrated new formulation. The Chuanxiong decoction integrated new formulation comprises the following active ingredient raw materials in part by weight: 10 parts of Chinese angelica and 10 parts of Chuanxiong. The production method of the Chuanxiong decoction integrated new formulation comprises the following steps: supersonic airflow crushing, alcohol water extraction, ultrasonic crushing and extraction, water decoction and concentration, supersonic spray drying, nanometer grinding, high-pressure homogenization, nanoparticle preparation and the like. The preparation method and the production method of the Chuanxiong decoction integrated new preparation pay attention to the advantages of multiple-collaboration, multiple targets and the like embodied by the application of a nano/carrier technology. After large-scale production, the production cost can be greatly reduced, the product quality can be greatly improved, and the targeting property and the sustained and controlled release property of drugs are stronger. The Chuanxiong decoction integrated new formulation can be internally and externally dosed and can also be taken at four time periods according to a midnight-noon ebb-flow and human body blood flow law. The Chuanxiong decoction integrated new formulation can also be prepared into a film agent and a transdermal agent, respectively stuck at different parts of a human body according to the midnight-noon ebb-flow and human body blood flow law and directly adsorbed by skin.
BACKGROUND: Magnesium sulfate, an intravenous adjuvant, has recently attracted immense attention in multimodal analgesia. Previous studies confirmed the crucial role of magnesium sulfate in postoperative pain and nociceptive hypersensitivity. However, the effect of magnesium sulfate in multimodal analgesia on the quality of recovery (QoR) for elderly patients has not been thoroughly studied. Therefore, the present experiment aimed to investigate the effect of continuous intravenous magnesium sulfate on the quality of postoperative recovery in elderly patients undergoing total knee arthroplasty (TKA).
PATIENTS AND METHODS: In this study, a total of 148 patients scheduled to undergo unilateral total knee arthroplasty were randomized into a magnesium sulfate group (Group M, n=68) and a control group (Group C, n=66) using a double-blind, randomized controlled trial. Before induction of anesthesia, Group M received intravenous magnesium sulfate (40 mg/kg) for 15 min, followed by a continuous infusion (15 mg/kg) until the end of the procedure. In the same manner, Group C received an infusion of the same amount of isotonic saline using the same method as the Group M.
RESULTS: Compared with Group C, Group M had significantly better QoR-15 scores on postoperative day 1(POD1) than Group C (P <0.05). Analysis of the dimensions of QoR-15 scores indicated that Group M exhibited notably reduced levels of pain, and higher levels of emotional state and physical comfort than Group C (P <0.05). Furthermore, Group C had significantly higher numerical rating scale (NRS) scores at POD1 than Group M (P <0.05).
CONCLUSION: For elderly patients undergoing knee arthroplasty, magnesium sulfate can be used as an adjuvant in a multimodal analgesic regimen to reduce early postoperative pain and improve the quality of early postoperative recovery.
This is a multicenter, randomized, open-label, phase Ib study to evaluate the safety, efficacy and pharmacokinetic characteristics of Mitoxantrone Hydrochloride Liposome in subjects with advanced solid tumor. 90 subjects will be recruited. The first 60 subjects will be randomly assigned into 2 groups, group A and group B. The 30 subjects in group A will receive the Mitoxantrone Hydrochloride Liposome 20 mg/m2 by an intravenous infusion (IV), every 28 days (q4w, 1 cycle). The 30 subjects in group B will receive Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, every 21 days (q3w, 1 cycle). After this, the last 30 subjects will be assigned into group B. All subjects will receive the treatment until disease progression, intolerable toxic reaction, death, or withdrawal by investigator or subject decision (a maximum of 8 cycles). Delays in drug administration is allowed from cycle 2, however, the delays should be no more than 3 weeks. Dose adjustments after cycle 2 is permitted, and the minimum dose is 12 mg/m2.
In year 1 of the two-part research study, an observational, prospective study of 75 Veterans preparing for elective surgery will be conducted. The purpose of this study will be to select appropriate nutrition screening and assessment tools and to employ them to characterize malnutrition prevalence and severity and establish cut-off values associated with malnutrition in this population. In years 2-5 of the research two-part research study, a pilot randomized controlled trial will be conducted. The purpose of this study will be evaluate the feasibility, fidelity, and acceptability of a perioperative protein-enhanced intervention compared to an educational control. Veterans who are malnourished or at risk of being malnourished will be randomly assigned on a 1:1 ratio to either an education (nutritional counseling) control or high-protein perihabilitation arm. Participants in the high-protein perihabilitation arm will be provided with 30 grams of high quality protein supplements three times per day. The study will take place two weeks prior to an elective abdominal or GI surgery and will continue 4 weeks post surgery.